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Beta (B.1.351)–variant coronavirus disease 2019 (COVID-19) 
disease was investigated in Qatar. Compared with the Alpha 
(B.1.1.7) variant, odds (95% confidence interval) of progressing 
to severe disease, critical disease, and COVID-19–related death 
were 1.24-fold (1.11–1.39), 1.49-fold (1.13–1.97), and 1.57-fold 
(1.03–2.43) higher, respectively, for the Beta variant.
Keywords. SARS-CoV-2; variant; infection; severe disease; 
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Commencing in mid-January 2021, Qatar experienced a severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Alpha 
[1] (B.1.1.7)–variant wave that peaked in the first week of March 
[2–5], but was immediately followed by a Beta [1] (B.1.351)–var-
iant wave that peaked in the first week of April [2–6]. This created 
a unique epidemiologic situation that allowed comparative as-
sessment of the severity, criticality, and fatality of these 2 variants.
METHODS
We investigated severity (acute-care hospitalization) [7], criti-
cality (intensive care unit [ICU] hospitalization) [7], and fatality 
[8] of both variants through 8 case-control studies applied to the 
complete national cohorts of SARS-CoV-2 infections, corona-
virus disease 2019 (COVID-19) disease cases, and COVID-19–
related deaths in Qatar, a country with diverse demographics 
where 89% of the population comprises expatriates from over 
150 countries [9]. Data on polymerase chain reaction (PCR) 
testing and clinical characteristics were extracted from the na-
tional federated COVID-19 databases that have captured all 
SARS-CoV-2–related data since the start of the epidemic. These 
databases were retrieved from the integrated nationwide digital-
health information platform (universal healthcare system), and 
include all records of PCR testing, antibody testing, vaccin-
ations, COVID-19 hospitalizations, infection severity classifica-
tion, and COVID-19–related deaths. Databases are complete at 
the national level with no missing information.
Records of PCR testing and clinical data for hospitalized pa-
tients with COVID-19 were examined. Details of the laboratory 
methods for PCR testing are found in Supplementary Text 1. 
Each person who had a PCR-positive test result and hospital 
admission was subject to an infection-severity assessment every 
3 days until discharge or death. Individuals who progressed to 
COVID-19 disease between the time of the PCR-positive test 
result and the end of the study were classified based on their 
worst outcome, starting with death [8], followed by critical di-
sease [7], and then severe disease [7].
Cases in the case-control studies were persons who pro-
gressed to COVID-19 severe disease, critical disease, or death. 
Controls were persons with asymptomatic or mild SARS-
CoV-2 infections. Cases and controls were matched at a ratio 
of 1:3 by 10-year age group, sex, and biweekly interval of the 
PCR diagnosis date. Every case in Qatar that met the inclusion 
criteria and that could be matched to a control was included in 
the study. Classification of case severity, criticality, and fatality 
followed the World Health Organization guidelines [7, 8], and 
assessments were made by trained medical personnel through 
individual chart reviews. Details of the COVID-19 severity, 
criticality, and fatality classification are found in Supplementary 
Text 2.
From 18 January until 15 February 2021, the Alpha-variant 
wave expanded rapidly and weekly rounds of viral genome 
sequencing [2–5] of randomly collected samples confirmed the 
presence of this and other originally circulating “wild-type” vari-
ants, but documented only limited presence of the Beta variant 
and no other variants of concern [2–5]. This allowed a compar-
ative assessment for the Alpha variant versus wild-type variants 
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during this specific time frame (Supplementary Text 3). From 8 
March through 31 May 2021, the Beta-variant wave expanded 
rapidly and viral genome sequencing [2–5] and multiplex quan-
titative reverse-transcription PCR (RT-qPCR) variant screening 
[2–6] indicated dominance of the Beta and Alpha variants, with 
limited presence of other variants [2–6]. This enabled compari-
sons between the Beta versus Alpha variants during this specific 
time frame (Supplementary Text 3). The Delta [1] (B.1.617.2) 
variant has been introduced more recently in Qatar, and it re-
mains at a low incidence as of 11 July 2021 [4–6]. Further details 
on the classification of infections by variant type are found in 
Supplementary Text 3.
Descriptive statistics (frequency distributions and meas-
ures of central tendency) were used to characterize the study 
samples. Two-sided P values of  less than .05 were considered 
statistically significant. Odds ratios and their associated 95% 
confidence intervals (CIs) were calculated using the exact 
method. Confidence intervals were not adjusted for multiplicity. 
Interactions were not investigated. Two sensitivity analyses were 
conducted by first adjusting for age, and second by adjusting for 
age and sex, in logistic regression analyses. Statistical analyses 
were conducted in STATA/SE version 17.0 (StataCorp).
The study was approved by the Hamad Medical Corporation 
and Weill Cornell Medicine–Qatar Institutional Review 
Boards with waiver of informed consent. Reporting of the 
study followed the STROBE (Strengthening the Reporting 
of Observational Studies in Epidemiology) guidelines 
(Supplementary Table 1).
RESULTS
Demographic characteristics of the samples for each disease 
outcome in assessing the severity, criticality, and fatality of the 
Alpha variant compared with the wild-type variants are pre-
sented in Supplementary Table 2. Compared with wild-type 
variants, the odds of progressing to severe disease were 1.48-
fold (95% CI: 1.18–1.84-fold) higher for the Alpha variant 
(Table 1). The odds of progressing to critical disease were 1.58-
fold (95% CI: .79–3.10-fold) higher, but did not reach statistical 
significance, perhaps because of the small number of critical di-
sease cases. There were also too few COVID-19–related deaths 
to assess the fatality of the Alpha variant.
The median time from PCR-positive test to severe disease was 
7 days (mean: 7 days; interquartile range [IQR]: 4–9 days) for 
Alpha cases and 6 days (mean: 6 days; IQR: 3–8 days) for wild-
type cases. The median time from severe to critical disease was 
4 days (mean: 5 days; IQR: 3–7 days) for Alpha cases and 4 days 
(mean: 6 days; IQR: 3–7 days) for wild-type cases. There were 
too few deaths in this analysis to provide summary statistics.
Demographic characteristics of the samples for each disease 
outcome in assessing the severity, criticality, and fatality of the 
Beta variant compared with the Alpha variant are presented in 
Supplementary Table 3. Compared with the Alpha variant, the 
odds of progressing to severe disease were 1.24-fold (95% CI: 
1.11–1.39-fold) higher for the Beta variant (Table 1). The odds 
of progressing to critical disease were 1.49-fold (95% CI: 1.13–
1.97-fold) higher, and the odds of COVID-19–related death 
were 1.57-fold (95% CI: 1.03–2.43-fold) higher.
Table 1. Infection Severity, Criticality, and Fatality of the Alpha and Beta Variants in the Population of Qatar
Groups Infection Severitya 
Assessment of Severity, Criticality, and Fatality of the Alpha 
Variant Compared With the Wild-type Variants Circulating 
Between 18 January and 15 February 2021b
Assessment of Severity, Criticality, and Fatality of the Beta 
Variant Compared With the Alpha Variant Between 8 March 
and 31 May 2021c
Infection  








a Beta Variant 
Infection With 
an Alpha Variant 
Odds Ratio 
(95% CI) 
Cases Severe disease 188 279 1.48 (1.18–1.84) 2036 483 1.24 (1.11–1.39)
Controls Asymptomatic or 
mild infection
431 944 5806 1707
Cases Critical disease 21 37 1.58 (.79–3.10) 382 81 1.49 (1.13–1.97)
Controls Asymptomatic or 
mild infection
49 125 1056 333
Cases Severe or critical 
disease
209 316 1.45 (1.18–1.79) 2418 564 1.28 (1.15–1.42)
Controls Asymptomatic or 
mild infection
480 1054 6764 2019
Cases COVID-19–related 
death
2 9 .83 (.07–5.58) 142 37 1.57 (1.03–2.43)
Controls Asymptomatic or 
mild infection
7 26 381 156
Cases and controls were matched on a ratio of 1:3 by 10-year age group, sex, and biweekly interval of the PCR diagnosis date.
Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
aSevere disease, critical disease, and COVID-19–related death were defined based on the World Health Organization criteria for classifying SARS-CoV-2 infection severity [7] and COVID-
19–related death [8].
bFrom 18 January to 15 February 2021, the Alpha variant and other wild-type variants dominated incidence, with limited presence of the Beta variant [2–5].
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The median time from PCR-positive test to severe disease 
was 5 days (mean: 5 days; IQR: 3–8 days) for Beta cases and 
5 days (mean: 6 days; IQR: 3–8 days) for Alpha cases. The me-
dian time from severe to critical disease was 7 days (mean: 9 
days; IQR: 4–11 days) for Beta cases and 7 days (mean: 10 days; 
IQR: 4–14 days) for Alpha cases. The median time from critical 
disease to death was 15 days (mean: 20 days; IQR: 6–26 days) 
for Beta cases and 15 days (mean: 21 days; IQR: 6–32 days) for 
Alpha cases.
Sensitivity analyses confirmed the above results 
(Supplementary Table 4).
DISCUSSION
The Alpha variant presented a 48% higher risk of severe disease 
than wild-type variants in the population of Qatar, affirming 
its greater gravity [10, 11] (odds ratio approximates risk ratio 
for rare outcomes). Infection with the Beta variant was asso-
ciated with even greater risks of severe and critical disease and 
COVID-19–related death, affirming earlier observational ana-
lyses suggesting its high gravity [11, 12]. Compared with the 
Alpha variant, infections with the Beta variant posed a 24% 
higher risk of severe disease, 49% higher risk of critical disease, 
and 57% higher risk of COVID-19–related death.
These results explain the changing pattern of hospitaliza-
tions and deaths seen during the Beta wave compared with the 
Alpha wave (Figure 1). Acute-care admissions doubled during 
the Beta wave, but ICU admissions and deaths quadrupled, with 
the disproportionally greater effect of this variant on critical di-
sease and COVID-19–related death.
Limitations include the smaller sample sizes of critical di-
sease and COVID-19–related deaths in the Alpha-variant anal-
ysis (Supplementary Table 2) compared with the Beta-variant 
analysis (Supplementary Table 3), as COVID-19 criticality 
Figure 1. Number of (A) daily new COVID-19 acute-care hospital admissions, (B) daily new COVID-19 ICU hospital admissions, and (C) COVID-19–related deaths in Qatar. 
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and fatality have been low in Qatar’s predominantly young 
and working-age population [9, 13], leading to statistically 
nonsignificant results and wider 95% CIs. Data on comorbid 
conditions were not available to study investigators; hence, they 
could not be explicitly factored in our analysis. Nevertheless, 
matching and adjusting for age in analysis may have served as 
a proxy, given that comorbidities are associated with old age. 
Furthermore, with the young population structure [9], we an-
ticipate that only a small proportion of the study population 
may have had serious comorbid conditions. However, our find-
ings may not be entirely generalizable to other settings, where 
elderly people constitute a sizable proportion of the population. 
Imperfect assay sensitivity and specificity of PCR testing may 
have affected infection ascertainment. However, all PCR testing 
was performed with extensively used, investigated, and valid-
ated commercial platforms having essentially 100% sensitivity 
and specificity (Supplementary Text 1). Unlike blinded ran-
domized clinical trials, the investigated observational cohorts 
were neither blinded nor randomized.
In conclusion, the Alpha variant is associated with a 48% 
higher risk of severe disease than wild-type variants. In turn, 
the Beta variant is associated with a 24% higher risk of severe 
disease than the Alpha variant, and strikingly, an even higher 
risk of critical disease (49%) and COVID-19–related death 
(57%). These findings highlight risks to healthcare systems, par-
ticularly intensive care facilities and resources, in the event of a 
globally increased circulation of the Beta variant. With the Delta 
variant increasingly dominating incidence in Qatar and other 
countries, an extension of this work could be a comparison of 
disease outcomes of Delta versus Alpha and Beta infections.
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